| Author, Year | Clinical Stage | No. of Patients | Chemo Rx | Radiation | No. Patients Resected (%) | Median Survival of Resected Patients (mo) |
| Evans [5] , 1992 | R | 28 | 5-FU | 50.4 Gy/S | 17 (61) | 18 |
| Yeung [59] , 1993 | R | 26 | 5-FU, MMC | 50.4 Gy/S | 12 (46) | OS: 8 |
| Pisters [60] , 1998 | R | 35 | 5-FU | 30 Gy/H Or 50.4 Gy/S | 20 (57) | 25 |
| Hoffman [61] , 1998 | R | 53 | 5-FU, MMC | 50 Gy/S | 24 (45) | 15.7 |
| White [62] , 2001 | R | 96 | 5-FU | 40 Gy/S | 53 (55) | 23 |
| Pisters [63] , 2002 | R | 37 | paclitaxel | 30 Gy/H, IORT | 20 (54) | 19 |
| Moutardier [64] , 2004 | R | 61 | 5-FU, cisplatin | 30 Gy/ SC or S | 40 (66) | 26.6 |
| Mournex [65] , 2005 | R | 41 | 5-FU, cisplatin | 50.4 Gy/S | 26 (63) | 12/5 |
| Talamonti [33] , 2006 | R | 20 | gemcitabine | 30 Gy/H | 17 (85) | 26 |
| Varadhachary [32] , 2008 | R | 90 | gemcitabine cisplatin | 30 Gy/H | 52 (58) | 31 |
| Evans [32] , 2008 | R | 86 | gemcitabine | 30 Gy/ H | 64 (74) | 34 |
| Turrini [66] , 2009 | R/BLR | 102 | 5-FU and cisplatin | 45 Gy | 62 (61)† | 23 |
| Le Scodan [67] , 2009 | R | 41 | 5-FU, cisplatin | 50 Gy | 26 (63) | 11.7 |
| Turrini [68] , 2010 | R | 34 | docetaxel | 45 Gy | 15 (44) | 32 |
| Stokes [52] , 2011 | BLR | 40 | capecitabine | 50 Gy | 16 (40) | 12 |
| Kang [69] , 2011 | BLR | 32 | No | 45 /50.4 Gy | 23 (72) | 26.3 |
| Artinyan [70] , 2011 | R | 39 | not available | not available | unknown | 33.8 |
| Lee [71] , 2012 | BLR* | 18 | gemcitabine | No | 17 | 23.1† |
| Sho [72] , 2012 | R BLR | 22 39 | gemcitabine | 50 /50.4 Gy | 59 (97) | 28† |
| Pipas [73] , 2012 | R BLR | 4 23 | gemcitabine and cetuximab | 54 Gy | 4 (100) 18 (78) | 24.3† |
| Arvold [74] , 2012 | BLR* | 24 | 5-FU orcapecitabine or gemcitabine | 50.4 Gy or CRT alone | 8 (30) | NR |
| Barugola [75] , 2012 | BLR* | 27 | gemcitabine, gemcitabine and cisplatin, or capecitabine | 50.6 Gy 45 Gy | NR | 35† |
| Leone [76] , 2013 | BR* | 15 | gemcitabine and oxaliplatin | 50.4 Gy | 9 (60) | 32† |
| Kim [35] , 2013 | R BR* | 23 39 | gemcitabine and oxaliplatin | 30 Gy | 13 (56) 24 (62) | 27.1† |
| Van Buren [77] , 2013 | R BR | 29 29 | gemcitabine and bevacizumab | 30 Gy | 43 (74) | 19.7 |
| Motoi [78] , 2013 | R BR | 19 16 | gemcitabine or S-1 | None | 30 (85) | 34.7 |
| Cho [79] , 2013 | BR | 30 | gemcitabine, +/− cisplatin or capecitabine | 45/50.4/58.4 Gy | NR | 45 |
| Rose [37] , 2014 | BR | 64 | gemcitabine, docetaxel | 50.4 Gy | 31 (48) | not reached at 21.6 months |
| O’Reilly [36] , 2014 | R | 38 | gemcitabine and oxaliplatin | No | 27 (71) | NR |
| Golcher [4] , 2014 | R | 33 | gemcitabine and cisplatin | 50.4 Gy | 19 (58) | 25 |
| Epelboym [80] , 2014 | BLR* | 134 | various chemotherapy | not available | 114 (80) | 27.3† |
| Blazer [81] , 2014 | BRPC | 18 | various regimens | 30/36 Gy | 11 (61) | NR |
| Christians [6] , 2015 | R | 69 | majority rec’d gemcitabine | 50.4 Gy | 60 (87) | 45 |
| Katz [82] , 2015 | BLR | 22 | FOLFIRINOX | 50.4 Gy | 15 (68) | NR |